Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers
Authors
Keywords
-
Journal
CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-12-09
DOI
10.1002/cncr.33364
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
- (2018) R D Kim et al. BRITISH JOURNAL OF CANCER
- Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
- (2018) Christopher P. Wardell et al. JOURNAL OF HEPATOLOGY
- Computer-based intensity measurement assists pathologists in scoring PTEN immunohistochemistry - Clinical associations in NSCLC patients of the ETOP Lungscape cohort
- (2018) Undine Rulle et al. Journal of Thoracic Oncology
- Mechanisms behind resistance to PI3K Inhibitor treatment induced by the PIM kinase
- (2018) Jin H. Song et al. MOLECULAR CANCER THERAPEUTICS
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
- (2017) Martin Dreyling et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- (2016) A. Patnaik et al. ANNALS OF ONCOLOGY
- Effects of PTEN gene alteration in patients with gallbladder cancer
- (2015) Asgar Ali et al. Cancer Genetics
- MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN
- (2015) Li-Juan Wang et al. Oncotarget
- Expression of PTEN in Endometrial Liquid-Based Cytology
- (2014) Alessia Di Lorito et al. ACTA CYTOLOGICA
- Best practice for PTEN gene and protein assessment in anatomic pathology
- (2013) Kátia C. Carvalho et al. ACTA HISTOCHEMICA
- Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
- (2013) Sumera Rizvi et al. GASTROENTEROLOGY
- Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues
- (2013) Oscar Maiques et al. HUMAN PATHOLOGY
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy
- (2013) Supak Yothaisong et al. TUMOR BIOLOGY
- The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas
- (2011) Dakeun Lee et al. MODERN PATHOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
- (2009) J W Valle et al. BRITISH JOURNAL OF CANCER
- Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells
- (2009) Kawin Leelawat et al. Cancer Cell International
- The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma
- (2009) J.-Y. Chung et al. CLINICAL CANCER RESEARCH
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started